Immunomodulatory and enhanced antitumor activity of a modified thymosin &agr;1 in melanoma and lung cancer

@article{Wang2018ImmunomodulatoryAE,
  title={Immunomodulatory and enhanced antitumor activity of a modified thymosin &agr;1 in melanoma and lung cancer},
  author={Fanwen Wang and Bin Li and Pengcheng Fu and Qingqing Li and Heng Zheng and Xingzhen Lao},
  journal={International Journal of Pharmaceutics},
  year={2018},
  volume={547},
  pages={611–620}
}
Graphical abstract Figure. No caption available. ABSTRACT Tumor‐targeted therapy is an attractive strategy for cancer treatment. Peptide hormone thymosin &agr;1 (T&agr;1) has been used against several diseases, including cancer, but its activity is pleiotropic. Herein, we designed a fusion protein T&agr;1‐iRGD by introducing the tumor homing peptide iRGD to T&agr;1. Results show that T&agr;1‐iRGD can promote T‐cell activation and CD86 expression, thereby exerting better effect and stronger… CONTINUE READING